DRUG · Mapped RxNorm record
Capecitabine
Normalized identity: capecitabine View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
NCT07222215
Study summary
ClinicalTrials.govPhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Elacestrant
Normalized identity: elacestrant View linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Metastatic Breast Cancerunresolved
Breast Cancerverified · MONDO: breast cancer
HER2- Breast Cancerunresolved
ESR1 Gene Mutationunresolved
ER Wildtypeunresolved
Breast Neoplasmsunresolved
Interventions
CapecitabineDRUG · verified · RxNorm: capecitabine
ElacestrantDRUG · verified · RxNorm: elacestrant
Sponsors & collaborators
Kristina A. Fanuccilead sponsor
Stemline Therapeutics, Inc.collaborator
Johns Hopkins Universitycollaborator
Translational Breast Cancer Research Consortiumcollaborator
Menarini Groupcollaborator
Gateway for Cancer Researchcollaborator
Terri Brodeur Breast Cancer Foundationcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07222215 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.